Septerna (NASDAQ:SEPN) Stock Price Down 3.9% - What's Next?

Key Points

• Septerna, Inc. (NASDAQ:SEPN) saw its stock price decline by 3.9%, trading at $14.15, with a significant drop in trading volume of 91% compared to average volumes.
• Analysts have varied opinions on Septerna, with ratings including a hold from Wall Street Zen, an overweight target from Cantor Fitzgerald at $25.00, and a buy recommendation from HC Wainwright with a $26.00 price objective.
• The company's recent earnings report showed a loss of ($0.56) EPS, missing expectations significantly, with projected earnings for the current fiscal year expected to remain negative at -7.11 EPS.

Septerna, Inc. (NASDAQ:SEPN - Get Free Report)'s stock price traded down 3.9% during trading on Thursday . The stock traded as low as $14.27 and last traded at $14.15. 60,214 shares traded hands during trading, a decline of 91% from the average session volume of 642,776 shares. The stock had previously closed at $14.72.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wall Street Zen raised shares of Septerna from a "sell" rating to a "hold" rating in a research note on Friday, September 5th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of Septerna in a research note on Friday, September 5th. Wells Fargo & Company increased their price target on shares of Septerna from $11.00 to $18.00 and gave the stock an "equal weight" rating in a research note on Friday, May 16th. Finally, HC Wainwright restated a "buy" rating and issued a $26.00 price objective on shares of Septerna in a report on Thursday, August 21st. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.75.

Septerna Stock Down 3.4%

The stock has a market cap of $633.66 million and a P/E ratio of -1.41. The business has a 50 day moving average price of $12.35 and a 200 day moving average price of $9.29.

Septerna (NASDAQ:SEPN - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The firm had revenue of $0.12 million during the quarter, compared to analysts' expectations of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. On average, research analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Septerna

A number of large investors have recently made changes to their positions in SEPN. Tower Research Capital LLC TRC acquired a new position in shares of Septerna in the 4th quarter valued at $25,000. BNP Paribas Financial Markets acquired a new stake in shares of Septerna during the 4th quarter valued at about $52,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Septerna during the 1st quarter valued at about $49,000. Zimmer Partners LP acquired a new stake in Septerna in the 4th quarter worth about $229,000. Finally, JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock worth $107,000 after buying an additional 1,315 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.